Table 2 Models output for assessing the variation in antibiotic consumption for the Haematology-Oncology general ward expressed as relative risk (RR) with 95%CI.
From: Impact of a two step antimicrobial stewardship program in a paediatric haematology and oncology unit
First intervention (FN institution guidelines publication and dissemination) | Second intervention (structured ASP) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immediate impact | Variation by months (slope variation) | Immediate impact | Variation by months (slope variation) | |||||||||
% | RR (95% CI) | p-value | % | RR (95% CI) | p-value | % | RR (95% CI) | p-value | % | RR (95% CI) | p-value | |
Total antibiotics | −11.3 | 0.89 (0.81–0.97) | 0.006 | −2.3 | 0.98 (0.97–0.99) | 0.000 | 2.9 | 1.03 (0.97–1.09) | 0.352 | −1.1 | 0.99 (0.98–1) | 0.003 |
Meropenem | −6.7 | 0.93 (0.7–1.24) | 0.635 | 6.3 | 1.06 (1.03–1.09) | 0.000 | −30.3 | 0.7 (0.58–0.83) | 0.000 | −3.7 | 0.96 (0.94–0.98) | 0.000 |
Piperacillin-tazobactam | 226.0 | 3.26 (2.45–4.34) | 0.000 | −11.0 | 0.89 (0.86–0.92) | 0.000 | 28.1 | 1.28 (1.11–1.48) | 0.001 | 1.2 | 1.01 (0.99–1.03) | 0.186 |
Third-generation cephalosporins | −77.6 | 0.22 (0.15–0.32) | 0.000 | −4.1 | 0.96 (0.93–0.99) | 0.008 | −0.4 | 1 (0.76–1.31) | 0.979 | −0.8 | 0.99 (0.96–1.02) | 0.604 |
Quinolones | 113.5 | 2.13 (1.38–3.3) | 0.001 | 23.0 | 1.23 (1.15–1.32) | 0.000 | 103.1 | 2.03 (1.4–2.94) | 0.000 | −14.3 | 0.86 (0.81–0.91) | 0.000 |
Amikacin | 10.1 | 1.1 (0.86–1.41) | 0.442 | −4.0 | 0.96 (0.94–0.99) | 0.002 | 14.6 | 1.15 (0.97–1.36) | 0.114 | −3.1 | 0.97 (0.95–0.99) | 0.003 |
Vancomycin-Teicoplanin | −24.8 | 0.75 (0.61–0.93) | 0.007 | −1.1 | 0.99 (0.97–1.01) | 0.269 | 1.2 | 1.01 (0.88–1.16) | 0.863 | −2.7 | 0.97 (0.96–0.99) | 0.001 |
